Falimint® (Falimint®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceAcetylaminonitropropoxybenzeneAcetylaminonitropropoxybenzene
Similar drugsTo uncover
  • Falimint®
    pills inwards 
    BERLIN-PHARMA, CJSC     Russia
    • Dosage form: & nbsppills
    Composition:

    In one pills contains:

    Nucleus: acetylaminonitropropoxybenzene 16.600 mg; sucrose - 249.984 mg; gelatin -2.016 mg; fat solid - 0.700 mg; talc - 7,700 mg; Copovidone - 9,000 mg; silicon dioxide colloid - 3,000 mg; magnesium stearate - 3,000 mg.

    Shell: acetylaminonitropropoxybenzene 8.400 mg; sucrose - 132.883 mg; talc - 0.160 mg; glucose syrup - 8.450 mg; simethicone emulsion 30% 0.024 mg; paraffin liquid - 0.066 mg; paraffin, solid - 0.041 mg.

    Description:Round, biconvex dragees of almost white color with a smooth surface, uniform in color.
    Pharmacotherapeutic group:Antiseptic
    ATX: & nbsp

    R.02.A.A   Antiseptics

    Pharmacodynamics:

    Antitussive, has analgesic, antiseptic effect. Eliminates unproductive irritating cough, with resorption creates a feeling of coolness in the mouth and larynx. Does not exert a drying effect on the mucous membranes, does not cause a feeling of numbness in the mouth.

    Pharmacokinetics:

    The maximum concentration of active substance in the blood plasma is detected through 1/2 -1 hour after taking the drug. Due to the high solubility in lipids and low solubility in water, acetylaminonitropropoxybenzene is excreted from the body with urine in a metabolized form.The concentration of metabolites reaches its maximum value in urine after 2 hours. Within 6 hours the main amount of metabolites is eliminated. After 24 hours in the urine, about 95% of the administered dose is found in the form of metabolites, in terms of the main metabolite - (3- (2-acetamino-4-nitro-phenoxy) propionic acid).

    Indications:

    Inflammatory diseases of the respiratory tract (tonsillitis, pharyngitis, laryngitis);

    inflammatory diseases of the oral cavity (gingivitis, stomatitis);

    reflex cough (unproductive, irritating);

    preparation for instrumental studies of the oral cavity and throat, the removal of molds and the fitting of dentures.

    Contraindications:

    Hypersensitivity to the components of the drug, pregnancy, lactation period, sugarase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption, children under 5 years.

    Pregnancy and lactation:

    Due to the lack of sufficient experience of use during pregnancy and lactation, it is not recommended to use the drug.

    Dosing and Administration:

    Dragee should be slowly dissolving in the mouth until completely dissolved.

    It is recommended for adults and children from 5 years every 2-3 hours to dissolve 1 tablet of the drug, without chewing.

    The maximum daily dose of 10 dragees.

    The drug is not intended for long-term use. It is not recommended to use the drug for more than 5 days without consulting a doctor.

    Side effects:

    Rarely: allergic reactions.

    Overdose:Cases of intoxication caused by the preparation of Falimint® are not known.
    Interaction:

    Not known.

    Special instructions:

    Do not use for prolonged use. After use, refrain from eating food and liquids, in order to avoid a decrease in the therapeutic effect.

    Patients with diabetes should take into account the sugar content in the preparation (1 dragee corresponds to 0.03 bread units).

    Effect on the ability to drive transp. cf. and fur:It is not known.
    Form release / dosage:

    Dragee 25 mg.

    Packaging:

    For 20 dragees in a blister of PVC / alum.

    1 blister in a cardboard box with instructions for use.

    Storage conditions:

    Store at a temperature not exceeding 25 ° C.

    Keep the medicine out of the reach of children!

    Shelf life:

    5 years

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N008973
    Date of registration:10.08.2010
    The owner of the registration certificate:BERLIN-PHARMA, CJSC BERLIN-PHARMA, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspBERLIN-CHEMI / MENARINI PHARMA GmbH BERLIN-CHEMI / MENARINI PHARMA GmbH Germany
    Information update date: & nbsp07.11.2013
    Illustrated instructions
      Instructions
      Up